82 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
2b/3a, Multi-Centre, Double-Blind, Placebo Controlled, Randomized Withdrawal Design Study to Evaluate the Efficacy and Safety of a Novel Oxypurinol … is a Phase 3, Multi-Centre, Double-Blind, Placebo Controlled, Randomized Withdrawal Design Study to Evaluate the Efficacy and Safety of a Novel Oxypurinol
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
in Registrant’s Certifying Accountant
Item 16G.
Corporate Governance
Item 16H.
Mine Safety Disclosure
Item 16I.
Disclosure Regarding Foreign Jurisdictions … authorities the safety, efficacy, and acceptable risk-to-benefit profile of our product candidates or any future product candidates;
the prevalence
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
the Efficacy and Safety of a Novel Oxypurinol Formulation in Patients with Progressing Stage 3-4 ADPKD and Coexistent Hyperuricemia. The XRX-OXY-201 … Trial is a Phase 3, Multi-Centre, Double-Blind, Placebo Controlled, Randomized Withdrawal Design Study to Evaluate the Efficacy and Safety of a Novel
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
2b/3a, Multi-Centre, Double-Blind, Placebo Controlled, Randomized Withdrawal Design Study to Evaluate the Efficacy and Safety of a Novel Oxypurinol … is a Phase 3, Multi-Centre, Double-Blind, Placebo Controlled, Randomized Withdrawal Design Study to Evaluate the Efficacy and Safety of a Novel Oxypurinol
424B3
a900j
13 Jun 24
Prospectus supplement
4:11pm
424B3
m785o3d4jiyn
13 Jun 24
Prospectus supplement
4:10pm
424B3
fs01ui
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
gne98itvts
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
uxg2gcf
3 Jan 24
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
7:25am
6-K
EX-10.1
7ck9p
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
6-K
EX-99.2
nl1ho7qw2p
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
6-K
EX-99.1
0v49r3xtx50wvfr5i4o
29 Aug 23
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
7:00am
424B3
vtt2d9j3 hv9n49k51
25 Aug 23
Prospectus supplement
6:00am
424B3
57gc35cz2rl7
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
octnuiwf7vd3lj7tten
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
fviin vetv00g2wsdy9e
14 Aug 23
Prospectus supplement
4:42pm
424B3
ancaok0y
14 Aug 23
Prospectus supplement
4:40pm